31 October 2024 ORYZON receives Notice of allowance for patent on novel technology for measuring LSD1 target engagement
24 October 2024 ORYZON reports financial results and corporate update for quarter ended September 30, 2024
1 October 2024 ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
23 September 2024 ORYZON presents the final data from PORTICO, a global Phase IIb vafidemstat trial in Borderline Personality Disorder (BPD), at the European College of Neuropsycopharmacology (ECNP) congress
11 September 2024 ORYZON receives “Intention to grant” communication for patent relating to the use of vafidemstat in Borderline Personality Disorder
9 September 2024 ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in first-line acute myeloid leukemia
3 September 2024 ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decision to grant” communications